公开(公告)号：US20240325457A1

公开(公告)日：2024-10-03

申请号：US18608371

申请日：2024-03-18

申请人： Doron Therapeutics, Inc. ,  Musculoskeletal Transplant Foundation

发明人： Alessandra PAVESIO ,  Carl FLANNERY ,  Scott SEAMAN ,  Michael A. NASERT ,  Eric J. SEMLER ,  Marc LONG

IPC分类号： A61K35/50 ,  A61K9/00 ,  A61K35/51 ,  A61K38/17 ,  A61K38/18 ,  A61K38/20 ,  A61K38/39 ,  A61K38/57 ,  A61P19/02

CPC分类号： A61K35/50 ,  A61K9/0019 ,  A61K35/51 ,  A61K38/1793 ,  A61K38/18 ,  A61K38/1825 ,  A61K38/2006 ,  A61K38/39 ,  A61K38/57 ,  A61P19/02

摘要： Provided herein are compositions containing dehydrated placental tissue particulates, methods of making the compositions and methods for treating various musculoskeletal disorders and other conditions using such compositions, including osteoarthritis (OA), degenerative disc disease, tendonitis, plantar fasciitis, and pain associated therewith.

公开(公告)号：US20240293471A1

公开(公告)日：2024-09-05

申请号：US18689276

申请日：2022-08-29

申请人： PLURI BIOTECH LTD.

发明人： Daniel ROTHENSTEIN ,  Yuval MATHEWS

IPC分类号： A61K35/50 ,  A61K9/00 ,  A61P9/10 ,  C12N5/073 ,  G01N33/66 ,  G01N33/68

CPC分类号： A61K35/50 ,  A61K9/0019 ,  A61P9/10 ,  C12N5/0605 ,  G01N33/66 ,  G01N33/6893 ,  G01N2333/805 ,  G01N2800/042

摘要： Disclosed herein are methods and compositions comprising placental adherent stromal cells for treating peripheral ischemic disease, for example critical limb ischemia in specific patient subpopulations; and methods of selecting subjects having peripheral ischemic disease, for example critical limb ischemia, amenable for treatment with placental adherent stromal cells.

公开(公告)号：US12048302B2

公开(公告)日：2024-07-30

申请号：US16807895

申请日：2020-03-03

申请人： Cook Biotech Incorporated

发明人： Umesh H. Patel ,  Michael L. Taylor ,  Claus Soendergaard ,  Cara McCammon ,  Rae Ritchie

IPC分类号： A01N1/02 ,  A61K35/50 ,  A61L27/36

CPC分类号： A01N1/0242 ,  A01N1/0221 ,  A01N1/0263 ,  A01N1/0268 ,  A61K35/50 ,  A61L27/3604 ,  A61L27/3683 ,  A61L27/3687

摘要： Disclosed are products having animal tissue packed within the lumen of a device such as a needle cannula and being therein impregnated with a cryopreservation medium. The needle cannula or other device can be received in a capsule and/or other container, which in some forms can contain additional amounts of the cryopreservation medium occurring external of the lumen. Methods of use of the products are also described and can include ejecting the animal tissue from the lumen of device using pressurized liquid passed through the lumen, potentially to deliver the animal tissue directly into a patient. Methods of manufacture of the products are also described.

公开(公告)号：US12011465B1

公开(公告)日：2024-06-18

申请号：US17879746

申请日：2022-08-02

申请人： Amnio Technology LLC

发明人： Robert B. Diller ,  Sarah Berglund

IPC分类号： A61K35/50 ,  A61K9/00 ,  A61K9/50 ,  A61K31/728 ,  A61K47/20

CPC分类号： A61K35/50 ,  A61K9/0024 ,  A61K9/5084 ,  A61K31/728 ,  A61K47/20

摘要： Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.

公开(公告)号：US20240173354A1

公开(公告)日：2024-05-30

申请号：US18442617

申请日：2024-02-15

申请人： EXOSTEM BIOTEC LTD.

发明人： Chaya BRODIE ,  Aharon BRODIE

IPC分类号： A61K35/28 ,  A61K35/50 ,  A61P21/00 ,  A61P43/00

CPC分类号： A61K35/28 ,  A61K35/50 ,  A61P21/00 ,  A61P43/00

摘要： Methods of treating an aging-associated disease, as well as inhibiting aging in a subject, by administering pharmaceutical compositions comprising unmodified and modified MSCs and their exosomes are provided.

公开(公告)号：US11992507B2

公开(公告)日：2024-05-28

申请号：US12161893

申请日：2007-01-23

申请人： Robert W. Mays ,  Robert J. Deans

发明人： Robert W. Mays ,  Robert J. Deans

IPC分类号： A61K35/28 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/485 ,  A61K31/52 ,  A61K31/661 ,  A61K35/12 ,  A61K35/30 ,  A61K35/407 ,  A61K35/44 ,  A61K35/48 ,  A61K35/50 ,  A61K35/51 ,  A61K35/545 ,  A61K38/13 ,  A61K45/06 ,  A61P25/00 ,  C12N5/074

CPC分类号： A61K35/50 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/485 ,  A61K31/52 ,  A61K31/661 ,  A61K35/12 ,  A61K35/28 ,  A61K35/30 ,  A61K35/407 ,  A61K35/44 ,  A61K35/48 ,  A61K35/51 ,  A61K35/545 ,  A61K38/13 ,  A61K45/06 ,  A61P25/00 ,  C12N5/0607 ,  A61K38/13 ,  A61K2300/00 ,  A61K35/545 ,  A61K2300/00

摘要： The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like with MAPCs, without the need for adjunctive immunosuppressive treatment.

公开(公告)号：US20240156875A1

公开(公告)日：2024-05-16

申请号：US18511853

申请日：2023-11-16

申请人： EquiStem Technology, LLC dba Equus Innovations

发明人： Christian Beaudry ,  Jaehyun Kim

IPC分类号： A61K35/50 ,  C12N5/073

CPC分类号： A61K35/50 ,  C12N5/0605

摘要： Equine-specific therapeutic compositions comprising placental-derived materials and methods of use, and method of producing said equine-specific therapeutic compositions that is clear, safe, and physiologically and biologically active liquid injectable. The tissue processing protocols described herein include methods for processing and decontaminating the incoming placental tissue and fluid having coloration and contaminants to produce a clear amnion and amniotic fluid injectable product while preserving postbiotics, proteins, exosomes, biocomponents and maintaining their physiological and biological properties.

公开(公告)号：US11944650B2

公开(公告)日：2024-04-02

申请号：US16833099

申请日：2020-03-27

申请人： The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： Frank Ho Pak Lau ,  Ian Hodgdon ,  Michael Cook

IPC分类号： A61K35/50 ,  A61B17/00 ,  A61F2/00 ,  A61K9/00 ,  A61L27/24 ,  A61L27/36 ,  A61L31/00 ,  A61L31/16 ,  A61P41/00

CPC分类号： A61K35/50 ,  A61F2/0063 ,  A61K9/0024 ,  A61L27/24 ,  A61L27/362 ,  A61L31/005 ,  A61L31/16 ,  A61P41/00 ,  A61B2017/00238 ,  A61F2002/0072 ,  A61F2220/0016 ,  A61L2430/34

摘要： A method of preventing or reducing the occurrence and/or development of a hernia within a subject at risk of developing a hernia includes implanting a graft material in contact with an opening in an abdominal wall. The graft material promotes healing of the abdominal wall and includes placental or placental derived tissue.

公开(公告)号：US11931458B2

公开(公告)日：2024-03-19

申请号：US17571658

申请日：2022-01-10

申请人： Babak Ghalili ,  Keyon Janani ,  Peter Scherp ,  John Borja

发明人： Babak Ghalili ,  Keyon Janani ,  Peter Scherp ,  John Borja

IPC分类号： A61K9/127 ,  A61K31/685 ,  A61K35/28 ,  A61K35/50 ,  A61K47/20 ,  A61K47/64 ,  C12N5/073 ,  C12N5/0775

CPC分类号： A61K9/127 ,  A61K31/685 ,  A61K35/28 ,  A61K35/50 ,  C12N5/0605 ,  C12N5/0662 ,  A61K47/20 ,  A61K47/645 ,  C12N2500/62

摘要： The present disclosure relates to exosome systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.

公开(公告)号：US20240066071A1

公开(公告)日：2024-02-29

申请号：US18036815

申请日：2021-11-16

申请人： NOVEOME BIOTHERAPEUTICS, INC.

发明人： Howard C. WESSEL ,  Larry R. BROWN ,  Ziv Z. KIRSHNER

IPC分类号： A61K35/50 ,  C12N5/073 ,  A61P25/00

CPC分类号： A61K35/50 ,  C12N5/0605 ,  A61P25/00

摘要： Molecular weight fractions of a conditioned medium of cultured amnion-derived multipotent progenitor cells, i.e., secretome fractions, and methods of processing a secretome such that it is separated into molecular weight fractions. Uses of the molecular weight secretome fractions to stimulate Schwann cell proliferation, promote neuroprotection, reduce retinal ganglion cell (RGC) loss, and reduce optic nerve inflammation in patients in need thereof.